Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minBullish
5 minStrong Bearish
Daily trend turns up above $4.46
Key levels
Resistance$3.40
Resistance$3.04
Support$2.32
Support$1.92
Latest news & SEC filings
ProductLarimar Therapeutics finishes rolling BLA submission for nomlabofusp
ProductLarimar Therapeutics finishes rolling BLA submission to FDA for nomlabofusp in Friedreich's ataxia
All LRMR news →Larimar Therapeutics develops medicines for uncommon illnesses, relying on a peptide-based delivery technology that helps therapies enter cells. Its main experimental drug, nomlabofusp, is given by injection and aims to restore a missing protein in the mitochondria of people who have Friedreich's ataxia. Testing is underway in the U.S., Canada, Europe, the U.K. and Australia, with participants ranging from young people to grown-ups.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
SEPT Low Target
$5.00
SEPT Mid Target
$9.50
SEPT High Target
$11.00
Analyst Consensus
$9.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LRMR.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$9.50
7
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
Insider Signal
BUYING
7 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Harlow John B. Jr. | officer | Buy | 50,000 | - | Sep 29, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
-59.0%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for LRMR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:58:54 | $2.71 | 1,000 | $$3K | MIDPOINT |
| 20:57:55 | $2.72 | 1,710 | $$5K | SELL |
| 20:54:52 | $2.72 | 1,000 | $$3K | BUY |
| 20:54:36 | $2.72 | 1,000 | $$3K | BUY |
| 20:50:15 | $2.70 | 1,000 | $$3K | SELL |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Larimar Therapeutics, Inc. (LRMR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Larimar Therapeutics, Inc. (LRMR) is at $2.73, up 1.49% (+$0.04) at the Nov 11, 2026 close.
Latest LRMR news — Nov 9, 2026: Larimar Therapeutics finishes rolling BLA submission for nomlabofusp · Nov 9, 2026: Larimar Therapeutics finishes rolling BLA submission to FDA for nomlabofusp in Friedreich's ataxia
The average analyst price target for LRMR is $9.50, ranging from $5 to $11, based on 4 analysts. Latest: Wedbush maintains on Aug 5, 2026.
Analyst ratings for LRMR: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
LRMR last reported on Aug 4, 2026: EPS -$0.30 vs -$0.38 expected — a beat of 21.4%.
LRMR does not currently pay a dividend.
Support: $2.32, $1.92, $1.61. Resistance: $3.04, $3.40, $3.70.
Insider activity: BUYING, 7 buys and 0 sells in the last 90 days.
Nov 9, 2026: Larimar Therapeutics finishes rolling BLA submission for nomlabofusp · Nov 9, 2026: Larimar Therapeutics finishes rolling BLA submission to FDA for nomlabofusp in Friedreich's ataxia